Derace L Schaffer Net Worth

The estimated Net Worth of Derace L Schaffer is at least $3.35 Milhão dollars as of 5 June 2019. Derace Schaffer owns over 10,000 units of Lantheus Inc stock worth over $1,732,538 and over the last 9 years Derace sold LNTH stock worth over $1,617,850.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Derace Schaffer LNTH stock SEC Form 4 insiders trading

Derace has made over 16 trades of the Lantheus Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Derace sold 10,000 units of LNTH stock worth $247,100 on 5 June 2019.

The largest trade Derace's ever made was buying 147,130 units of Lantheus Inc stock on 22 December 2017 worth over $258,949. On average, Derace trades about 25,685 units every 34 days since 2016. As of 5 June 2019 Derace still owns at least 16,994 units of Lantheus Inc stock.

You can see the complete history of Derace Schaffer stock trades at the bottom of the page.

What's Derace Schaffer's mailing address?

Derace's mailing address filed with the SEC is C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA, MA, 01862.

Insiders trading at Lantheus Inc

Over the last 9 years, insiders at Lantheus Inc have traded over $500,725,766 worth of Lantheus Inc stock and bought 8,000 units worth $141,200 . The most active insiders traders include David F Burgstahler, Capital Partners Gp, Llc Av..., eSriram Venkataraman. On average, Lantheus Inc executives and independent directors trade stock every 11 days with the average trade being worth of $15,777,680. The most recent stock trade was executed by James H Thrall on 21 August 2024, trading 1,000 units of LNTH stock currently worth $98,520.

What does Lantheus Inc do?

lantheus holdings, inc. (nasdaq: lnth) is the parent company of lantheus medical imaging, inc. (lmi), which is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. lmi provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. lmi’s key products include the echocardiography contrast agent definity® vial for (perflutren lipid microsphere) injectable suspension; technelite® (technetium tc99m generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and xenon (xenon xe 133 gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. the company is headquartered in north billerica, massachusetts with offices in puerto rico and canada. for more information, visit www.lantheus.com.

Complete history of Derace Schaffer stock trades at Altimmune Inc e Lantheus Inc

Lantheus Inc executives and stock owners

Lantheus Inc executives and other stock owners filed with the SEC include:

• Mary Heino,
  President, Chief Executive Officer, Director
• Robert Marshall,
  Chief Financial Officer, Treasurer
• Mary Anne Heino,
  CEO, Pres & Director
• Michael Duffy,
  Senior Vice President, Law and Public Policy and General Counsel
• John Bolla,
  Chief Operating Officer, Senior Vice President, Technical Operations
• Simon Robinson,
  Senior Vice President - Research and Pharmaceutical Development
• Robert J. Marshall Jr., CFA,
  CFO & Treasurer
• Paul M. Blanchfield,
  Chief Operating Officer
• Daniel M. Niedzwiecki,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Brian Markison,
  Non-Executive Independent Chairman of the board
• Samuel Leno,
  Independent Director
• Frederick Robertson,
  Independent Director
• James Clemmer,
  Independent Director
• Gary Pruden,
  Independent Director
• Julie McHugh,
  Independent Director
• James Thrall,
  Independent Director
• Heinz Maeusli,
  Independent Director
• Gerard Ber,
  Independent Director
• Istvan Molnar,
  Chief Medical Officer
• Paul Blanchfield,
  Chief Commercial Officer
• Carol Walker,
  Senior Vice President - Quality
• Etienne Montagut,
  Senior Vice President - Corporate Development
• Etienne Montagut,
  Chief Bus. Officer
• Carol Walker,
  Sr. VP of Quality
• Ying Yao,
  Chief HR Officer
• Melissa Downs,
  Director of Corp. Communications
• Linda S. Lennox,
  VP of Corp. Communications & Chief of Staff
• Mark Richard Kinarney,
  Sr. Director of Investor Relations
• Andrea Sabens,
  Principal Accounting Officer
• Capital Partners Gp, Llc Av...,
  
• David F Burgstahler,
  Director
• Cesare Orlandi,
  Chief Medical Officer
• Derace L Schaffer,
  Director
• Sriram Venkataraman,
  Director
• Timothy G Healey,
  SVP, Commercial
• Daniel Niedzwiecki,
  See Remarks
• Ying Vivian Yao,
  Chief Human Resources Officer
• Minnie Baylor Henry,
  
• Andrea Sabens,
  Chief Accounting Officer
• Kenneth Pucel,
  Director
• John W. Crowley,
  VP Finance and Accounting
• John K Bakewell,
  CFO and Treasurer
• Patrick O'neill,
  Director
• William C. Jr. Dawes,
  VP Mfrg and Operations
• Jeffrey Allen Bailey,
  CEO and President
• Kimberly Brown,
  Chief Accounting Officer
• Jeffrey Humphrey,
  Chief Medical Officer
• Sam R Leno,
  
• Jean Claude Provost,
  Chief Medical Officer